It is made available under a CC-BY 4.0 International license .

#### 1 The Pattern of rpoB gene mutation of *Mycobacterium tuberculosis* and predictors of

2 rifampicin resistance detected by gene Xpert MTB/Rif in Tanzania.

# 3 Authors

- 4 Peter Richard Torokaa<sup>1,2\*</sup>, Heledy Kileo<sup>3</sup>, Loveness Urio<sup>2</sup>, Mariam R. Mbwana<sup>1,2</sup> Mariam C.
- 5 Monah<sup>1,2</sup>, Sephord Saul Ntibabara<sup>1,2</sup>, Jasper Kimambo<sup>1,2</sup>, Paschal Seleman<sup>3</sup>, Collins Franklin<sup>3</sup>,
- 6 Robert Balama<sup>3</sup>, Riziki M. Kisonga<sup>3</sup>, Mtebe V. Majigo<sup>4</sup>, Agricola Joachim<sup>4</sup>

# 7 Affiliations

- <sup>8</sup> <sup>1</sup>Muhimbili University of Health and Allied Sciences, School of Public Health and Social Sciences,
- 9 Dar es Salaam, Tanzania.
- <sup>10</sup> <sup>2</sup>Tanzania Field Epidemiology and Laboratory Training Program, Dar es Salaam, Tanzania.
- <sup>3</sup>Ministry of Health, National TB and Leprosy Program, Dodoma Tanzania.
- <sup>4</sup>Muhimbili University of Health and Allied Sciences, College of Medicine, Dar es Salaam,
- 13 Tanzania
- 14 \*Corresponding Author: Peter Torokaa, Email: <u>petertorokaa@gmail.com (PRT)</u>

# 15 ABSTRACT

# 16 Introduction

Antimicrobial resistance associated with *Mycobacterium tuberculosis (*MTB) is the challenge facing Tuberculosis (TB) management worldwide. Rifampicin resistance (RR) has been associated with the rpoB gene mutation. No study was conducted in Tanzania to determine the commonest mutation. The inconsistent findings from various studies support the need to determine whether

It is made available under a CC-BY 4.0 International license .

reported mutation patterns are applicable in our setting. We determined the frequency of rpoB gene
mutation and factors associated with RR detected using GeneXpert MTB/Rif.

# 23 Methods

We conducted a retrospective cross-sectional study involving data from the National Tuberculosis and Leprosy Program database from 2020 to 2022 for cases investigated using GeneXpert. Descriptive analysis was performed as the frequency for categorical variables. The chi-square test and regression analysis assessed the relationship between the independent variables and outcome. The 95% confidence interval and a significance level of p<0.05 were used to assess the association strength.

# 30 **Results**

A total of 56,004 participants had status of MTB and RR. Most, 38,705/56,004 (69.11%) were male. 31 Probe E, 89/219 (40.64%) was the predominant. Human immunodeficiency virus (HIV)-positive 32 patients had a higher gene mutation, 134/10601 (1.26%) than HIV-negative, 306/45016 (0.68%) 33 (p<0.001). Patients with both pulmonary and extra-pulmonary TB had about four times greater odds 34 of developing rifampicin resistance (AOR 3.88, 95%CI: 1.80 - 8.32). RR was nearly nine times 35 higher in previously treated patients than new patients (AOR 8.66, 95%CI: 6.97-10.76). HIV-36 positive individuals had nearly twice the odds of developing RR than HIV-negative individuals 37 38 (AOR 1.91, 95%CI: 1.51 – 2.42).

# 39 Conclusion

The rate of RR was low compared to other studies in Tanzania, with probe E mutations the most
prevalent. Patients with disseminated TB, HIV co-infection and those with prior exposure to anti-

It is made available under a CC-BY 4.0 International license .

- 42 TB had more risk of RR. The findings highlight the need to strengthen surveillance of multidrug-
- 43 resistant-TB among patients with a higher risk of RR.
- 44 Keywords: *Mycobacterium tuberculosis*, rifampicin resistance, GeneXpert, probe mutations,
  45 Tanzania

## 46 Introduction

47 Multidrug-resistant Mycobacterium tuberculosis (MDR-TB) is the biggest challenge facing Tuberculosis (TB) care and treatment worldwide (1). MDR-TB is a major contributor to global 48 antimicrobial resistance (AMR) and continues to pose a public health threat (1–3). MDR-TB is 49 considered when there is resistance to isoniazid and rifampicin, with or without resistance to other 50 first-line drugs. The main problem is rifampicin resistance, the most potent first-line treatment (1). 51 Patients with rifampicin-resistant TB or MDR-TB require a second-line treatment regimen (4). 52 Globally, the annual estimated number of MDR-TB or rifampicin-resistant TB cases was steady 53 between 2015 and 2020; however, it increased in 2021. In 2021, it was estimated to be 450,000 54 events, a 3.1% increase from 437,000 in 2020 (1). 55

The World Health Organization (WHO) developed a strategy to end TB-related deaths, illnesses, and suffering by 2035 (5). It recommends accelerating the identification and enhancing treatment for MDR-TB. Apart from access to diagnosis, adequate infection control must also be implemented in the settings where patients are treated (4). To diagnose MDR-TB, WHO recommends more specific and sensitive assays like real-time polymerase chain reaction (RT-PCR), DNA microarray, and loop-mediated isothermal amplification (LAMP). These technologies determine the mutations in the genes to identify drug resistance. In some populations of HIV-infected presumptive TB

It is made available under a CC-BY 4.0 International license .

patients, the lateral flow lipoarabinomannan assay (LF-LAM) test is advised to aid in the diagnosisof TB (6).

65 The invention of the Xpert® MTB/RIF Assay (Cepheid, USA), which simultaneously detects the presence of Mycobacterium tuberculosis (MTB) and rifampicin resistance, has transformed the 66 diagnosis of TB. Rifampicin inhibits DNA-directed RNA synthesis of MTB proteins by binding to 67 68 the subunit of the bacterial DNA-dependent RNA polymerase (rpoB) enzyme. Rifampicin resistance has been associated with the rpoB gene mutation. Almost 96.1% of rifampicin-resistant 69 70 MTB strains have *rpoB* mutations (7). The rifampicin resistance is the proxy sign of the MDR-TB (8,9). GeneXpert/MTB RIF is a cartridge-based, automated hemi-nested-nested real-time 71 Polymerase Chain Reaction (PCR) system that utilizes five overlapping probes named Probe A 72 (codons 507-511), Probe B (codons 511-518), Probe C (codons 518-523), Probe D (codons 523-73 529) and Probe E (codons 529–533) (10). 74

Studies in Africa revealed that the commonest mutation of rpoB occurs at probes E and D (11–13). However, the literature shows different pattern distributions of the rpoB gene mutation of MTB associated with drug resistance (11–13). There is a need to determine whether the findings in other studies apply to our setting due to the varied findings obtained in various geographical areas. No other study has been conducted in Tanzania to reveal the patterns of rpoB mutation. Due to efforts to increase access to GeneXpert MTB/RIF diagnosis in the country, there is also a need to determine the factors associated with Rifampicin-resistant TB.

## 82 Methods

#### 83 Study design and setting

We conducted a retrospective cross-sectional study involving the Tanzania National Tuberculosis and Leprosy Program (NTLP) data collected from January 2020 through December 2022. The study covered Presumptive TB cases notified to NTLP from 26 regions of Tanzania's mainland. The NTLP is tasked with preventing tuberculosis and leprosy as serious public health concerns in Tanzania, and it was launched in 1977 as a single combined programme for the two diseases.

#### 89 Data collection

We extracted demographic and clinical data from eTL and laboratory results from gxalert databases on 10<sup>th</sup> October, 2023 and then exported them to Microsoft Excel. The demographic data from the eTL register and laboratory results data were linked between these two databases. The identifiers used to link the two databases were patient name, health facilities, district, and year. The variables of interest from the two databases were demographic characteristics (age, gender, residence), clinical characteristics (TB treatment history, type of TB, bacillary load, HIV status), and geneXpert results.

#### 97 Data analysis

We presented the descriptive analysis with frequency distributions (%) for categorical variables and a mean was a measure of central tendency for age. Regression analyses (bivariate and multivariate) were performed to assess the relationship between demographic and clinical characteristics as independent variables and the rifampicin resistance as an outcome variable. Factors with a p-value of 0.20 in the bivariate analyses were included in the multivariable model using forward selection. The 95% confidence interval (CI) was presented, and a significance level of p <0.05 was used.</p>

# 104 **Results**

105	We extracted data for 112,768 nonrepeating patients tested for TB using GeneXpert. Of all, 56,662
106	(50.2%) had laboratory-confirmed TB. Rifampicin resistance was identified in 450/56,662 (0.8%)
107	patients with MTB. The specific gene mutations in the rpoB gene of Mycobacterium tuberculosis
108	were identified in the form of the missing probes, which indicated a specific mutation occurs at a
109	specific codon in the rpoB gene named Probe A (codons 507-511), Probe B (codons 511-518),
110	Probe C (codons 518–523), Probe D (codons 523–529), and Probe E (codons 529–533). Missing
111	probes (specific rpoB mutation detected) were found in 219/450 (48.7%) samples with Rifampicin-
112	resistant MTB, and no missing probes (no specific rpoB mutation detected) in 231/450 (51.3%)
113	with Rifampicin-resistant. Rif Indeterminate were observed in 658/56,662 (1.16%) of patients with
114	MTB and were excluded in further analysis (Fig 1).
114 115	MIB and were excluded in further analysis (Fig 1).
	Fig 1. Flow chart of participants' analysis
115	
115 116	Fig 1. Flow chart of participants' analysis
115 116 117	Fig 1. Flow chart of participants' analysis Demographic and clinical characteristics of study participants
115 116 117 118	Fig 1. Flow chart of participants' analysis Demographic and clinical characteristics of study participants A total of 56,004 participants had clear status of MTB and rifampicin resistance. Most of them,
115 116 117 118 119	<ul> <li>Fig 1. Flow chart of participants' analysis</li> <li>Demographic and clinical characteristics of study participants</li> <li>A total of 56,004 participants had clear status of MTB and rifampicin resistance. Most of them, 38,705/56,004 (69.11%) were male. The age group 35- 44 years accounted for the largest cases,</li> </ul>
115 116 117 118 119 120	<ul> <li>Fig 1. Flow chart of participants' analysis</li> <li>Demographic and clinical characteristics of study participants</li> <li>A total of 56,004 participants had clear status of MTB and rifampicin resistance. Most of them, 38,705/56,004 (69.11%) were male. The age group 35- 44 years accounted for the largest cases, 13,512/56,004 (24.13%). Most participants, 55,192/56,004 (98.55%), had pulmonary TB.</li> </ul>

124 The regional distribution of cases is shown in Fig 2.

#### 125 Table 1. Participants' demographic and clinical characteristics (N=56,004)

Variable	Frequency	Percent (%)
Age Group (years)		
<15	1765	3.15

It is made available under a CC-BY 4.0 International license .

Variable	Frequency	Percent (%)
15-24	6441	11.5
25-34	12637	22.56
35-44	13512	24.13
45-54	10460	18.68
>55	11189	19.98
Mean age (SD)	41(16.4)	
Gender		
Male	38705	69.11
Female	17299	30.89
ТВ Туре		
Pulmonary	55192	98.55
Extra pulmonary	550	0.98
Pulmonary and extra pulmonary	262	0.47
Treatment History		
New patient	53818	96.1
Previous treated	2186	3.9
HIV status		
Positive	10601	18.93
Negative	45016	80.38
Unknown	387	0.69

126

#### 127 Fig 2. Map showing the proportion distribution of study participants per region

## 128 Pattern of specific rpoB gene mutations in MTB

129 Specific mutations (missing probe) were detected in 219/450 (48.7%) rifampicin-resistant TB. The

most prevalent mutation, 89/219 (40.64%), occurred at Probe E, followed by Probe D, 44/219

131 (20.09%), and the least mutation, 10/219 (4.56%), occurred at Probe C. We found a mutation

- 132 combination of Probe A and B, 5/219 (2.28%), Probe A and D, 2/219 (0.91%), Probe A and E 1/219
- 133 (0.46%), and Probe B and E 1/219 (0.46%). One patient had a triple mutation combination at Probe
- 134 A, D, and E 1/219 (0.46%) (Table 2).
- 135 Table 2. Frequency and distribution of specific rpoB gene mutations (N=219)

It is made available under a CC-BY 4.0 International license .

Probe B       511–518       39       1         Probe C       518–523       10       4         Probe D       523–529       44       24         Probe E       529–533       89       4         Probe A+B       5       2       0         Probe A+D       2       0       0         Probe A+E       1       0       0	Probes	#Codons	Frequency	Percent (%)
Probe C       518–523       10       4         Probe D       523–529       44       24         Probe E       529–533       89       4         Probe A+B       5       2       0         Probe A+D       2       0       0         Probe A+E       1       0       0	Probe A	507–511	21	9.59
Probe D       523–529       44       24         Probe E       529–533       89       4         Probe A+B       5       2         Probe A+D       2       0         Probe A+E       1       0	Probe B	511–518	39	17.81
Probe E       529–533       89       4         Probe A+B       5       2         Probe A+D       2       0         Probe A+E       1       0	Probe C	518–523	10	4.57
Probe A+B52Probe A+D20Probe A+E10	Probe D	523–529	44	20.09
Probe A+D20Probe A+E10	Probe E	529–533	89	40.64
Probe A+E 1	Probe A+B		5	2.28
	Probe A+D		2	0.91
	Probe A+E		1	0.46
Probe B+E 1 0	Probe B+E		1	0.46
Probe A+D+E 1	Probe A+D+E		1	0.46

136

#### 137 The proportion of participants with no missing probe

Specific rpoB mutation were not detected (no missing probe) in 231/450 (51.3%) participants with Rifampicin-resistance. We found that no missing probes were significantly higher in new TB patients, 189/334 (56.59%) compared to previously treated patients, 42/116(36.21%) (p = 0.003). Patients with a very low TB bacillary load, 199/263 (75.67%), had a higher number of no missing probes when compared with other categories (p<0.001). There was no statistically significant difference of no missing probes for other variables (Table 3).

# Table 3. Demographic and Clinical characteristics of the number of no-missing probe study participants (N=450)

Variable	Total	# No missing probe	Proportion	P value
	Rifampicin			
	Resistant			
Age Group				
<15	6	3	50.00	
15-59	376	185	49.20	
>59	68	43	63.24	0.103
Gender				

It is made available under a CC-BY 4.0 International license .

Variable	Total	# No missing probe	Proportion	P value
	Rifampicin		_	
	Resistant			
Male	312	168	53.85	
Female	138	63	45.65	0.133
ТВ Туре				
Pulmonary	438	224	51.14	
Extra pulmonary	5	2	40.00	
Pulmonary and extra pulmonary	7	5	71.43	0.59
Treatment History				
New patient	334	189	56.59	
Previous treated	116	42	36.21	0.003
HIV status				
Positive	134	59	44.03	
Negative	306	167	54.58	0.12
<b>Bacillary Load</b>				
High	61	10	16.39	
Medium	66	5	7.58	
Low	60	17	28.33	
Very low	263	199	75.67	< 0.001

146

## 147 Rifampicin resistance and participant characteristics

GeneXpert detects the mutation in the rpoB mutations, and the final results are provided as 148 rifampicin-resistant. The rpoB gene mutation was higher in 15-59-year-old patients, 383/45,782 149 150 (0.84%) compared to other age groups (p = 0.047). More mutations were found in patients with pulmonary and extra-pulmonary TB patients (7/262, 2.67%) than in pulmonary or extra-pulmonary 151 alone (p = 0.003). Furthermore, we found that previously treated patients had a higher mutation 152 rate, 116/2186 (5.31%), compared to new patients (p<0.001). HIV-positive TB patients had a higher 153 gene mutation, 134/10601 (1.26%), than HIV-negative, 306/45016(0.68%) (p<0.001). Other 154 variables like gender and point of health service showed no significant difference in gene mutation 155 (Table 4). 156

157

It is made available under a CC-BY 4.0 International license .

Variable	Total participants	# Total RR	Proportion	P value
Age Group				
<15	1765	6	0.34	
15-59	45782	383	0.84	
>59	8457	61	0.72	0.047
Gender				
Male	38705	312	0.81	
Female	17299	138	0.80	0.918
ТВ Туре				
Pulmonary	55192	438	0.79	
Extra pulmonary	550	5	0.91	
Pulmonary and extra pulmonary	262	7	2.67	0.003
Treatment History				
New patient	53818	334	0.62	
Previous treated	2186	116	5.31	< 0.001
HIV status				
Positive	10601	134	1.26	
Negative	45016	306	0.68	< 0.001
Referral type				
Community	46897	364	0.78	
Health facility	6167	60	0.97	
Others	2940	26	0.88	0.234

#### 158 Table 4. Distribution of rifampicin resistance and participants' characteristics (N=56,004))

159 \*\* The frequency for HIV status is less due to unknown status.

#### 160 **Predictors of rifampicin resistance**

161 Compared to pulmonary TB, patients with both pulmonary and extra-pulmonary TB had about four 162 times greater odds of developing rifampicin resistance (AOR 3.88, 95%CI: 1.80 – 8.32). The 163 likelihood of rifampicin resistance was nearly nine times higher in previously treated patients 164 compared to new (AOR 8.66, 95%CI: 6.97 – 10.76). HIV-positive individuals had nearly twice the 165 odds of developing rifampicin resistance than HIV-negative individuals (AOR 1.91, 95%CI: 1.51 166 – 2.42) (Table 5).

#### 167 Table 5. Multivariate Logistic regression analysis for the predictors of Rifampicin resistance

It is made available under a CC-BY 4.0 International license .

Characteristic	Rif. resistance	COR (95% CI)	<b>P-value</b>	AOR (95% CI)	P-
	n (%)				value
Age Group					
<15	6 (0.34)	Ref		Ref	
15-59	383 (0.84)	2.47 (1.10 - 5.55)	0.028	2.07 (0.92 - 4.67)	0.078
>59	61 (0.72)	2.13 (0.92 - 4.93)	0.078	1.95 (0.84 - 4.54)	0.119
ТВ Туре					
Pulmonary	438 (0.79)	Ref		Ref	
Extra pulmonary	5 (0.91)	1.15 (0.47 – 2.78)	0.762	1.19 (0.49 – 2.92)	0.694
Pulmonary and extra pulmonary	7 (2.67)	3.43 (1.61 -7.31)	0.001	3.88 (1.80 - 8.32)	0.001
Treatment History					
New patient	334 (0.62)	Ref		Ref	
Previous treated	116 (5.31)	8.97 (7.23 – 11.13)	< 0.001	8.66 (6.97 – 10.76)	<0.001
HIV status					
Negative	306 (1.26)	Ref		Ref	
Positive	134 (0.68)	1.87 (1.53 – 2.29)	< 0.001	1.82 (1.44 - 2.30)	<0.001
Referral type					
Community	364 (0.78)	Ref		Ref	
Health facility	60 (0. 97)	1.25 (0.95 – 1.65)	0.104	0.83 (0.61 – 1.14)	0.250
Others	26 (0.88)	1.14 (0.76 – 1.70)	0519	0.99 (0.66 - 1.48)	0.969

168

# 169 **Discussion**

170	The current study found that the most prevalent mutation in rpoB gene mutation in MTB was at
171	probe E codon (529–533) (40.64%), followed by Probe D codon (523–529) 20.09% which was
172	similar to studies done in Nigeria, Uganda, Pakistan, Addis Ababa Ethiopia, and Bangladesh (13-
173	17), the similarities suggests that a significant number of low-income individuals migrating for
174	shelters may be responsible for the spread of mutant strains within the community (18). Our findings
175	differed from the study done in Northeast India and Enugu, South Eastern Nigeria, which revealed
176	that the most prevalent mutations were detected at probes A and D, respectively (19,20). The
177	differences might be attributed to geographical differences caused by the variations in the $M$ .

It is made available under a CC-BY 4.0 International license .

*tuberculosis* lineage (21). According to the results of our study and previous studies, probe E is
linked to the most common probe mutation in the rpoB gene mutation.

180 The study found that new TB patients had a significantly higher number of specific rpoB mutations 181 not detected among those with rifampicin resistance than previously treated patients. Our finding is similar to a Northeast India study (20). This may result from an early stage of TB diagnosis, which 182 183 may have a low bacillary load. No missing probe may also be triggered by various probes having varying target hybridization dynamics, which might have a higher impact after extended PCR cycles 184 (22). Patients with low TB bacillary load also had more no-missing probes. This could mean 185 GeneXpert testing in patients with less advanced disease and lower bacterial density (new patients) 186 is considered less accurate in detecting rifampicin-resistant tuberculosis (23). The very low bacillary 187 load on GeneXpert testing was shown to be substantially linked to false rifampicin resistance during 188 the initial GeneXpert assay (22). The samples with very low bacillary load were not retested; hence, 189 190 the rate of false positives for rifampicin resistance could not be determined.

191 The rifampicin resistance was found more in patients with both pulmonary and extra-pulmonary TB than in pulmonary or extra-pulmonary alone. In addition, patients with both pulmonary and 192 193 extra-pulmonary TB had almost four times greater odds of developing rifampicin resistance. Our findings were comparable to the study done in the Debre Markos Referral Hospital Ethiopia (24). 194 195 We also found that previously treated patients had significantly higher rifampicin resistance than new patients. The likelihood of rifampicin resistance was nearly nine times higher in previously 196 treated patients than in new patients, similar to the study done in Nepal (25). Our findings support 197 198 that MTB increases the ability to develop resistance when exposed to anti-TB drugs, especially in 199 patients with poor adherence to treatment (26). In our study, the odds of developing rifampicin

It is made available under a CC-BY 4.0 International license .

resistance in previously treated patients were higher than in Somalia and other East Gojjam zone
northwest Ethiopia studies, which revealed four and six times, respectively (27,28).

202 HIV-positive TB patients had a higher gene mutation than HIV-negative. HIV-positive individuals 203 had nearly twice the odds of developing rifampicin resistance than HIV-negative individuals; this was similar to the studies done in northwest Ethiopia (27,29). Variations in TB/HIV co-infection 204 205 have been reported in several studies, indicating challenges in diagnosis and treatment due to unusual clinical presentations and difficulties in diagnosis and treatment (30–32). This may be due 206 207 to differences in TB control strategies and approaches (29). More rifampicin-resistant MTB in HIV patients might be caused by poor treatment adherence. Poor adherence to treatment is the primary 208 factor contributing to drug resistance (25,31). This highlights the need for more surveillance and 209 community involvement. 210

The study had limitations, including missing variables and being unable to confirm false positive rates for rifampicin resistance at low bacillary load. However, the large sample size of participants from all Tanzania mainland regions made the findings representative and generalisable to all regions.

# 215 Conclusion

The rate of rifampicin resistance in our study was low compared to other studies done in Tanzania. The Probe E (codons 529–533)-related mutations were the most prevalent rpoB gene mutation. Patients with disseminated TB, HIV co-infection and those with prior exposure to anti-TB are associated with rifampicin resistance. The findings highlight the need to strengthen the surveillance of MDR-TB among patients identified with a higher risk of rifampicin resistance.

It is made available under a CC-BY 4.0 International license .

# 221 Ethical considerations

Ethical approval was obtained from the MUHAS Senate Research and Publications Committee of Muhimbili University of Health and Allied Sciences, Ref. No. DA.282/298/01L/629. Approval to use the national TB program data was obtained from the NTLP Program Manager in the Ministry of Health (MoH). The data was routinely collected by health facilities providing TB care and treatment services in which ethical issues are strongly advocated.

# 227 Author contributions

PRT, AJ, HK, MVM and LU authors contributed equally to the design. PRT, MRM, MCM, SSN,
RMK, CF, RB, PS and JK did data collection and write-up of this manuscript. AJ and MVM
reviewed the manuscript. All authors read and approved the final manuscript.

## 231 Acknowledgments

We are very grateful to the Muhimbili University of Health and Allied Sciences, Ministry of Health,
 NTLP program, Tanzania Field Epidemiology and Laboratory program for technical support of this
 study.

## 235 **References**

1. Global Tuberculosis report 2022. 2022. Available from: <u>http://apps.who.int/bookorders.</u>.

Yan Shao, Dandan Yang, Weiguo Xu, Wei Lu, Honghuan Song, Yaoyao Dai, Hongbing
 Shen & Jianming Wang. Epidemiology of anti-tuberculosis drug resistance in a chinese
 population: Current situation and challenges ahead. BMC Public Health. 2011;11.
 https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-11-110#Abs1

It is made available under a CC-BY 4.0 International license .

241	3.	Molla KA, Reta MA, Ayene YY. Prevalence of multidrug-resistant tuberculosis in East
242		Africa: A systematic review and meta-analysis. PLoS One. 2022 Jun 1;17(6 June). https://
243		doi: 10.1371/journal.pone.0270272.

- 4. Tuberculosis: Multidrug-resistant tuberculosis (MDR-TB). <u>https://www.who.int/news-</u>
   room/questions-and-answers/item/tuberculosis-multidrug-resistant-tuberculosis-(mdr-tb)
- 5. World Health Organization. The End Strategy TB. End TB Strateg. 2015;53(9):1689–99.
  https://www.who.int/publications-detail-redirect/WHO-HTM-TB-2015.19
- 248 6. World Health Organization (WHO). WHO operational handbook on tuberculosis. Module 3:
- Diagnosis Rapid diagnostics for tuberculosis detection 2021 update
   https://apps.who.int/iris/bitstream/handle/10665/340256/9789240022614-eng.pdf
- 7. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of
  Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient
  technology. J Clin Microbiol. 2010;48(1):229–37. <u>https://doi: 10.1128/JCM.01463-09. Epub</u>
  2009 Oct 28.
- Unit MR, Health P, Hospital D, Grove ED. The rapid diagnosis of isoniazid and rifampicin
   resistance in. 1998;47:189–96. J Med Microbiol. 1998 Mar;47(3):189-96.
   https://doi:10.1099/00222615-47-3-189.
- 258 9. Tao N. Risk factors for drug- resistant tuberculosis , the association between resistant
  259 comorbidity status and drug- patterns : a retrospective study of previously treated
  260 pulmonary tuberculosis in Shandong , China , during 2004 2019. 2021;1–9. <u>http://doi:</u>
  261 10.1136/bmjopen-2020-044349.

- 10. Akalu GT, Tessema B, Petros B. High proportion of RR-TB and mutations conferring RR
  outside of the RRDR of the rpoB gene detected in GeneXpert MTB/RIF assay positive
  pulmonary tuberculosis cases, in Addis Ababa, Ethiopia. PLoS One. 2022;17(12
  December):1–18. http://dx.doi.org/10.1371/journal.pone.0277145
- Reta MA, Alemnew B, Abate BB, Fourie PB. Prevalence of drug resistance-conferring
   mutations associated with isoniazid- and rifampicin-resistant Mycobacterium tuberculosis in
   Ethiopia: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2021;26:207–
- 269 18. <u>https://doi.org/10.1016/j.jgar.2021.06.009</u>
- Lavu EK, Johnson K, Banamu J, Pandey S, Carter R, Coulter C, et al. Drug-resistant
  tuberculosis diagnosis since Xpert ® MTB/RIF introduction in Papua New Guinea, 2012–
  2017 . Public Heal Action. 2019;9(1):S12–8. https://doi:10.5588/pha.19.0005.
- 273 13. Mboowa G, Namaganda C, Ssengooba W. Rifampicin resistance mutations in the 81 bp
- 274 RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert® MTB/RIF
- in Kampala, Uganda: A retrospective study. BMC Infect Dis. 2014 Sep 4;14(1):1–5.
- 276 https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-14-481
- Ullah I, Shah AA, Basit A, Ali M, khan A, Ullah U, et al. Rifampicin resistance mutations in
  the 81 bp RRDR of rpoB gene in Mycobacterium tuberculosis clinical isolates using Xpert
  MTB/RIF in Khyber Pakhtunkhwa, Pakistan: A retrospective study. BMC Infect Dis.
- 280 2016;16(1):4–9. <u>http://dx.doi.org/10.1186/s12879-016-1745-2</u>
- 15. Alemu A, Tadesse M, Seid G, Mollalign H, Eshetu K, Sinshaw W, et al. Does Xpert®
  MTB/RIF assay give rifampicin resistance results without identified mutation? Review of
  cases from Addis Ababa, Ethiopia. BMC Infect Dis. 2020;20(1):1–6. <a href="https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi:https://doi</a>

It is made available under a CC-BY 4.0 International license .

#### 284 <u>10.1186/s12879-020-4817-2</u>

- 16. Uddin MKM, Rahman A, Ather MF, Ahmed T, Rahman SMM, Ahmed S, et al. Distribution
  and frequency of rpob mutations detected by xpert MTB/RIF assay among beijing and non-
- beijing rifampicin resistant Mycobacterium tuberculosis isolates in Bangladesh. Infect Drug
- 288 Resist. 2020;13:789–97. https://www.dovepress.com/infection-and-drug-resistance-journal
- 17. Ochang EA, Udoh UA, Emanghe UE, Tiku GO, Offor JB, Odo M, et al. Evaluation of
   rifampicin resistance and 81-bp rifampicin resistant determinant region of rpoB gene
   mutations of Mycobacterium tuberculosis detected with XpertMTB/Rif in Cross River State,
- 292 Nigeria. Int J Mycobacteriology. 2016;5:S145–6.
   293 http://dx.doi.org/10.1016/j.ijmyco.2016.09.007
- 18. Adhikari S, Saud B, Sunar S, Ghimire S, Yadav BP. Status of rpoB gene mutation associated
  with rifampicin-resistant Mycobacterium tuberculosis isolated in a rural setting in Nepal.
- 296 Access Microbiol. 2021;3(3):10–3. <u>https://DOI: 10.1099/acmi.0.000202</u>
- Ugwu KO, Onah IS, Mbah GC, Ezeonu IM. Rifampicin resistance patterns and dynamics of
   tuberculosis and drug-resistant tuberculosis in Enugu, South Eastern Nigeria. J Infect Dev
   Ctries. 2020;14(9):1011–8. https://doi:10.3855/jidc.12736.
- 300 20. Sailo CV, Lalremruata R, Sanga Z, Fela V, Kharkongor F, Chhakchhuak Z, et al. Distribution
- and frequency of common mutations in rpoB gene of Mycobacterium tuberculosis detected
- 302 by Xpert MTB/RIF and identification of residential areas of rifampicin resistant-TB cases: J
- Clin Tuberc Other Mycobact Dis. <u>https://doi.org/10.1016/j.jctube.2022.100342</u>
- 21. Ektefaie Y, Dixit A, Freschi L, Farhat MR. Globally diverse Mycobacterium tuberculosis
   resistance acquisition: a retrospective geographical and temporal analysis of whole genome


It is made available under a CC-BY 4.0 International license .

- 306 sequences. The Lancet Microbe. 2021;2(3):e96–104. <u>http://dx.doi.org/10.1016/S2666-</u>
   307 <u>5247(20)30195-6</u>
- 308 22. Ngabonziza JCS, Decroo T, Migambi P, Habimana YM, Van Deun A, Meehan CJ, et al.
- 309 Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a
- prospective observational study in Rwanda. The Lancet Microbe [Internet]. 2020;1(2):e74–
- 311 83. http://dx.doi.org/10.1016/S2666-5247(20)30007-0
- 312 23. Variava E, Moloantoa T, Martinson NA. Discrepancies in Xpert tuberculosis testing. The
- 313 Lancet Microbe [Internet]. 2020 Jun 1 [cited 2023 Nov 30];1(2):e47–8.
- 314 <u>http://www.thelancet.com/article/S2666524720300331/fulltext</u>
- 315 24. Mulu W, Abera B, Yimer M, Hailu T, Ayele H, Abate D. Rifampicin-resistance pattern of
- 316 Mycobacterium tuberculosis and associated factors among presumptive tuberculosis patients
  317 referred to Debre Markos Referral Hospital, Ethiopia: a cross-sectional study. BMC Res
- 318 Notes. 2017;10(1):1–8. https://doi.org/10.1186/s12879-019-3943-1
- 319 25. Sah SK, Bhattarai PR, Shrestha A, Dhami D, Guruwacharya D, Shrestha R. Rifampicin-
- 320 resistant mycobacterium tuberculosis by genexpert mtb/rif and associated factors among
- 321 presumptive pulmonary tuberculosis patients in nepal. Infect Drug Resist. 2020;13:2911–9.
- 322 https://www.dovepress.com/infection-and-drug-resistance-journal
- Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in SubSaharan Africa: how strongly associated with previous treatment and HIV co-infection?
  Ethiop J Health Sci. 2013;23(3):271–82. https://doi:10.4314/ejhs.v23i3.10.
- 326 27. Adane K, Ameni G, Bekele S, Abebe M, Aseffa A. Prevalence and drug resistance profile of
  327 Mycobacterium tuberculosis isolated from pulmonary tuberculosis patients attending two


It is made available under a CC-BY 4.0 International license .

328	public hos	pitals in	East Goijar	n zone, northwes	st Ethiopia	Infectious	Disease e	pidemiology.
-----	------------	-----------	-------------	------------------	-------------	------------	-----------	--------------

- BMC Public Health. 2015;15(1):1–8. <u>https://doi:10.1186/s12889-015-1933-9</u>
- Ali MM, Weldegebreal F, Kabew G, Urgesa K. Rifampicin resistant Mycobacterium
  tuberculosis and associated factors among presumptive pulmonary tuberculosis patients in
- 332
   Mogadishu, Somalia. SAGE Open Med. 2023;11. <a href="https://doi:10.1177/20503121221148603">https://doi:10.1177/20503121221148603</a>
- Ayalew ML, Yigzaw WB, Tigabu A, Tarekegn BG. Prevalence, associated risk factors
  rifampicin resistance pattern of pulmonary tuberculosis among children at debre markos
  referral hospital, Northwest, Ethiopia. Infect Drug Resist. 2020;13:3863–72.
- 336 <u>https://DOI:10.2147/IDR.S277222</u>
- 337 30. Yitayew YA, Bekele DM, Wondimeneh B, Menji DZA. Mother to child transmission of HIV
  and associated factors among HIV exposed infants at public health facilities, Dessie town,
  Ethiopia. HIV/AIDS Res Palliat Care. 2019;11:343–50. https://doi:10.2147/HIV.S221409
- 340 31. Diriba K, Awulachew E, Churiso G. The magnitude of mtb and rifampicin resistance mtb
  341 using xpert-mtb/rif assay among tuberculosis suspected patients in gedeo zone, southern
  342 ethiopia. Infect Drug Resist. 2021;14:3961–9.
  343 https://doi:10.2147/IDR.S327607.eCollection2021
- Jaganath D, Zalwango S, Okware B, Nsereko M, Kisingo H, Malone LS, et al. Contact
  investigation for active tuberculosis among child contacts in Uganda. Clin Infect Dis.
  2013;57(12):1685–92: https://doi:10.1093/cid/cit645



# Figure



Figure